The drug of choice following surgery to adjuvant chemotherapy

Breast cancer is a serious impact on women's mental and physical health and even life-threatening, one of the most common malignant tumor in recent years, the incidence rising, after lung cancer, a major cause of death of female cancers. However, the fact the majority of patients with early breast cancer can be cured completely. Early discovery, timely surgery, optimization of treatment programs, as well as physical and psychological concerns for patients are the ultimate rehabilitation to help patients regain a new life elements.

Recently, Sanofi - aventis Group, the media communication will be held, from Jiao Tong University, Ruijin Hospital, Professor Shen Kunwei, Fudan University Cancer Hospital of Military Medical Sciences Professor Shao Zhimin, as well as 307 affiliated hospitals, Professor Jiang Zefei and to all the media on breast Cancer chemotherapy and rehabilitation of the latest progress of the exchange.

Surgical treatment of breast cancer is currently the primary means of selecting suitable drugs postoperative adjuvant chemotherapy, can significantly reduce the risk of tumor recurrence and improve survival. BCIRG001 large-scale international multi-center clinical study showed that compared with the traditional programs, including Taxotere in adjuvant chemotherapy can reduce the risk of tumor recurrence 28%, reduce the risk of death by 30%. At the same time, a large number of evidence-based medical research has also indicated that in order to docetaxel-based adjuvant chemotherapy can be effective treatment programs and high-risk axillary lymph node-positive early breast cancer axillary lymph node-negative patients, thereby reducing recurrence and prolong survival time, to make life quality can be improved.

Based on the above findings, docetaxel has been the United States, European Union and China approved for adjuvant chemotherapy for early breast cancer and become the U.S. National Comprehensive Cancer Network (NCCN) and other authoritative guidelines recommended standard one of the options. Globally, Taxotere has treated more than 900,000 patients with breast cancer. Meanwhile, at which Professor Jiang Zefei also pointed out: "breast cancer patients choose a suitable adjuvant chemotherapy drugs can really improve the patient's chances of survival, for early stage breast cancer is very important to choose the best treatment options should be promoted in front of a good medicine , so that patients have the opportunity to cure. " Treatment of early breast cancer are: cure cancer, reduce the risk of postoperative tumor recurrence and death, to extend the disease-free survival, thus prolonging survival time. Taxotere is currently the only access to SFDA approved for early breast cancer adjuvant chemotherapy docetaxel.

As the breast cancer disease, its specificity, the patient will suffer from breast cancer itself and the lack of a double blow, in the rehabilitation and treatment, they may occur will be faced with the pressure of the tumor metastasis as well as the treatment brought pain, these patients would give a huge psychological impact. Data show that the psychological barrier of patients with breast cancer incidence is much higher than other cancer patients, many patients after surgery for a long time, there exists a higher anxiety and depression. Therefore, to help patients make the necessary psychological rehabilitation is essential. At the same time, a thorough treatment of early breast cancer and to reduce damage to the breast surgery was also crucial, the doctor can be taken before surgery chemotherapy (neoadjuvant chemotherapy), followed by breast-conserving surgery, in the premise of keeping healthy, but also to stay live beautiful, for patients in the future physical and psychological rehabilitation of the two parties to create favorable conditions.